1. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
- Author
-
Schackman BR and Eggman AA
- Subjects
- Cost-Benefit Analysis, Female, Humans, Male, South Africa, United States, Anti-HIV Agents administration & dosage, Anti-HIV Agents economics, Chemoprevention economics, Chemoprevention methods, HIV Infections prevention & control
- Abstract
Purpose of Review: The US Food and Drug Administration (FDA) recently approved the use of tenofovir-emtricitabine for pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP is also being investigated in clinical trials as a component of HIV prevention in resource-limited settings. Cost-effectiveness models are useful in identifying health programs with the greatest societal value and projecting long-term program impacts. This review examines six recent studies of the cost-effectiveness of PrEP for preventing HIV transmission in the USA and South Africa., Recent Findings: Studies used both individual-level and population-level transmission models. PrEP was found to be a cost-effective HIV-prevention intervention in high-risk MSM with HIV incidence at least 2% in the USA (
- Published
- 2012
- Full Text
- View/download PDF